These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37871728)

  • 1. Detergent-free parasite transformation and replication assay for drug screening against intracellular Leishmania amastigotes.
    Sifontes-Rodríguez S; Escalona-Montaño AR; Sánchez-Almaraz DA; Pérez-Olvera O; Aguirre-García MM
    J Microbiol Methods; 2023 Dec; 215():106847. PubMed ID: 37871728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line.
    Jain SK; Sahu R; Walker LA; Tekwani BL
    J Vis Exp; 2012 Dec; (70):. PubMed ID: 23299097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An axenic amastigote system for drug screening.
    Callahan HL; Portal AC; Devereaux R; Grogl M
    Antimicrob Agents Chemother; 1997 Apr; 41(4):818-22. PubMed ID: 9087496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro and In Vivo Antileishmanial Activity of Thioridazine.
    Sifontes-Rodríguez S; Mollineda-Diogo N; Monzote-Fidalgo L; Escalona-Montaño AR; Escario García-Trevijano JA; Aguirre-García MM; Meneses-Marcel A
    Acta Parasitol; 2024 Mar; 69(1):324-331. PubMed ID: 38070122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
    Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
    Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery.
    Aulner N; Danckaert A; Rouault-Hardoin E; Desrivot J; Helynck O; Commere PH; Munier-Lehmann H; Späth GF; Shorte SL; Milon G; Prina E
    PLoS Negl Trop Dis; 2013; 7(4):e2154. PubMed ID: 23593521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of NanoLuc-PEST expressing Leishmania mexicana as a new drug discovery tool for axenic- and intramacrophage-based assays.
    Berry SL; Hameed H; Thomason A; Maciej-Hulme ML; Saif Abou-Akkada S; Horrocks P; Price HP
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006639. PubMed ID: 30001317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alkylaminoalkanethiosulfuric acids exhibit in-vitro antileishmanial activity against Leishmania (Viannia) braziliensis: a new perspective for use of these schistosomicidal agents.
    Porcino GN; Antinarelli LMR; Maia ACRG; Faria-Pinto P; Taunay-Rodrigues A; Zech Coelho PM; Nelson DL; Penido MLO; Coimbra ES; Vasconcelos EG
    J Pharm Pharmacol; 2019 Dec; 71(12):1784-1791. PubMed ID: 31579947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties.
    Corman HN; Ross JN; Fields FR; Shoue DA; McDowell MA; Lee SW
    Microbiol Spectr; 2022 Dec; 10(6):e0265822. PubMed ID: 36342284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening.
    Sereno D; Roy G; Lemesre JL; Papadopoulou B; Ouellette M
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1168-73. PubMed ID: 11257031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of luciferase expressing Leishmania donovani axenic amastigotes as primary model for in vitro screening of antileishmanial compounds.
    Ravinder ; Bhaskar ; Gangwar S; Goyal N
    Curr Microbiol; 2012 Dec; 65(6):696-700. PubMed ID: 22945482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.
    Vermeersch M; da Luz RI; Toté K; Timmermans JP; Cos P; Maes L
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3855-9. PubMed ID: 19546361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of (-)α-bisabolol as a promising agent against Leishmania amazonensis.
    Rottini MM; Amaral AC; Ferreira JL; Silva JR; Taniwaki NN; Souza Cda S; d'Escoffier LN; Almeida-Souza F; Hardoim Dde J; Gonçalves da Costa SC; Calabrese Kda S
    Exp Parasitol; 2015 Jan; 148():66-72. PubMed ID: 25448354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative Activity and Ultrastructural Changes in Promastigote and Amastigote forms of Leishmania amazonensis Caused by Limonene-Acylthiosemicarbazide Hybrids.
    Graça Contato A; Kaplum V; Botura Scariot D; Pelegrin Garcia F; Falzirolli H; Vandresen F; Ueda-Nakamura T; de Oliveira Silva S; Conceição da Silva C; Vataru Nakamura C
    Chem Biodivers; 2023 Jul; 20(7):e202300523. PubMed ID: 37263974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit.
    De Muylder G; Ang KK; Chen S; Arkin MR; Engel JC; McKerrow JH
    PLoS Negl Trop Dis; 2011 Jul; 5(7):e1253. PubMed ID: 21811648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170.
    de Sousa Araújo PS; de Oliveira SSC; d'Avila-Levy CM; Dos Santos ALS; Branquinha MH
    Parasitol Res; 2018 Jul; 117(7):2085-2094. PubMed ID: 29728827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileishmanial Activity, Cytotoxicity and Mechanism of Action of Clioquinol Against Leishmania infantum and Leishmania amazonensis Species.
    Tavares GSV; Mendonça DVC; Lage DP; Granato JDT; Ottoni FM; Ludolf F; Chávez-Fumagalli MA; Duarte MC; Tavares CAP; Alves RJ; Coimbra ES; Coelho EAF
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):236-246. PubMed ID: 29481714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro drug susceptibility using a parasite-rescue and transformation assay of Leishmania (Mundinia) martiniquensis and Leishmania (Mundinia) orientalis amastigotes against antileishmanial drugs.
    Kimcharoensuk S; Leelayoova S; Mungthin M; Nawattanapaibool N; Tan-Ariya P; Siripattanapipong S
    Acta Trop; 2024 Jan; 249():107081. PubMed ID: 37993039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.
    Villa-Pulgarín JA; Gajate C; Botet J; Jimenez A; Justies N; Varela-M RE; Cuesta-Marbán Á; Müller I; Modolell M; Revuelta JL; Mollinedo F
    PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005805. PubMed ID: 28829771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites.
    Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F
    PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.